Zurcher Kantonalbank Zurich Cantonalbank Has $189,000 Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 18.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,097 shares of the company’s stock after selling 1,781 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Akero Therapeutics were worth $189,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Strs Ohio lifted its holdings in shares of Akero Therapeutics by 100.0% during the 4th quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $46,000 after buying an additional 1,000 shares during the last quarter. Orion Capital Management LLC bought a new stake in Akero Therapeutics in the third quarter worth approximately $51,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Akero Therapeutics by 352.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,449 shares of the company’s stock worth $151,000 after purchasing an additional 5,023 shares during the last quarter. Amalgamated Bank increased its stake in shares of Akero Therapeutics by 18.2% during the 3rd quarter. Amalgamated Bank now owns 7,559 shares of the company’s stock worth $382,000 after purchasing an additional 1,166 shares during the last quarter. Finally, E Fund Management Co. Ltd. raised its holdings in shares of Akero Therapeutics by 10.8% during the 3rd quarter. E Fund Management Co. Ltd. now owns 9,428 shares of the company’s stock valued at $477,000 after purchasing an additional 918 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have recently issued reports on AKRO shares. HC Wainwright upped their price target on Akero Therapeutics from $40.00 to $43.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Bank of America initiated coverage on Akero Therapeutics in a research report on Monday, April 22nd. They set a “neutral” rating and a $30.00 target price for the company. Finally, UBS Group lifted their price target on shares of Akero Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $37.71.

Akero Therapeutics Stock Performance

NASDAQ AKRO opened at $22.02 on Wednesday. The company has a quick ratio of 29.27, a current ratio of 29.27 and a debt-to-equity ratio of 0.05. The company’s 50-day simple moving average is $24.17 and its 200 day simple moving average is $21.14. The stock has a market cap of $1.52 billion, a P/E ratio of -7.73 and a beta of -0.29. Akero Therapeutics, Inc. has a twelve month low of $11.25 and a twelve month high of $58.38.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.17). As a group, research analysts forecast that Akero Therapeutics, Inc. will post -3.93 earnings per share for the current fiscal year.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, COO Jonathan Young sold 5,000 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $20.15, for a total transaction of $100,750.00. Following the sale, the chief operating officer now owns 258,306 shares of the company’s stock, valued at approximately $5,204,865.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Akero Therapeutics news, insider Catriona Yale sold 20,646 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $35.49, for a total value of $732,726.54. Following the transaction, the insider now directly owns 78,415 shares in the company, valued at approximately $2,782,948.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jonathan Young sold 5,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $20.15, for a total value of $100,750.00. Following the sale, the chief operating officer now owns 258,306 shares of the company’s stock, valued at approximately $5,204,865.90. The disclosure for this sale can be found here. Insiders sold 105,646 shares of company stock valued at $3,420,627 over the last ninety days. 9.69% of the stock is owned by insiders.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.